Cladribine

Cladribine (2-Chlordeoxyadenosine) is a synthetic purine nucleoside that is converted to an active cytotoxic metabolite by the deoxycytidine kinase. The drug is relatively selective for both normal and malignant lymphoid cells. 

Cladribine is highly active against hairy cell leukemia (complete remssions were achieved in more than 60% of patients receiving a single 7-day course). Activity has been recorded in other low-grade lymphoid malignancies. The major side effect is myelosuppression. 

C29H42ClN50sSSi2 149681-75-4) see Cladribine 2-[(4-chlarophenyl)acetyl]benzoic acid (C15H11CIO3 53242-76-5) see Azelastine a-chlorophenylacetyl chloride... 

C7H5CIO2 1885-14-9) see Alacepril Camazepam Itraconazole Paroxetine t>-phenyl chlorothioformate (C7H5CIOS 1005-56-7) see Cladribine 4-phenylcinnoline... 

Cladribine -as therapy for low-grade or mantle cell lymphoma... 

Cladribine (2-CdA) -purine analogue antimetabolite -bone marrow suppression -fever in 50% (probably due to tumor lysis) -rash in 50% -immunosuppression (with profound T-cell lymphopenia)... 

Cladribine, or 2-chlorodeoxyadenosine, is resistant to adenosine deaminase and after intracellular phosphorylation by deoxycytidine kinase, it is incorporated into DNA. It is considered the drug of choice in hairy cell leukemia because of high activity combined with acceptable toxicity. Cladribine shows variable oral absorbtion and is usually administered intravenously. Its concentration-time course is biphasic with plasma half-lives of 35 minutes and 6.7 hours. Excretion is primarily by the kidneys. Its most prominent dose-limiting toxicity is myelosup-pression. 

---